Merck (MRK, $78.58) Q1 earnings beat estimates, as Keytruda sales surge +55%
Merck first quarter earnings surpassed analysts’ estimates, thanks in large part to its success in lung cancer treatment.
For the three months ending in March, the pharma company’s GAAP earnings came in at $1.12 per share, beating the Street consensus estimates by seven cents. The earnings per share more than quadrupled from the year-ago quarter.
Merck’s total revenues surged +8% year-over-year to $10.8 billion, on the back of a +55% sales growth of Keytruda lung cancer treatment.
CEO Ken Frazier highlighted investments in research and development as one of the factors behind Merck’s strong quarter.
Looking ahead, Merck lifted its full-year 2019 revenue outlook to a range of $43.9 to $45.1 billion, while forecasting GAAP earnings to range between $4.02 and $4.12 per share.
The company also revealed a global restructuring plan - which includes closing plants and slashing jobs - that is expected to get completed by 2023. According to Merck, pre-tax charge of between $800 million and $12 billion will mostly go towards paying employee separation and plant closure costs.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for MRK shows an upward move is likely
MRK's Aroon Indicator triggered a bullish signal on August 24, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 255 similar instances where the Aroon Indicator showed a similar pattern. In of the 255 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on MRK as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on August 13, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRK broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.208) is normal, around the industry mean (19.422). MRK's P/E Ratio (125.160) is considerably higher than the industry average of (33.317). Projected Growth (PEG Ratio) (10.734) is also within normal values, averaging (11.305). Dividend Yield (0.022) settles around the average of (0.027) among similar stocks. P/S Ratio (5.831) is also within normal values, averaging (4.270).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
Advertisement